Immune mediated disease Flashcards

1
Q

What are the two main types of immune responses?

A

Innate immunity: Immediate, non-specific (e.g. macrophages, NK cells)

Adaptive immunity: Slower but specific (e.g, T-cells, B-cells, antibodies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the key failure in immune-mediated diseases?

A

Failure of self-tolerance (usually peripheral) leading to immune system attacking body’s own healthy cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the two types of immune tolerance?

A

Central tolerance: Deletion of self-reactive T-cells in thymus

Peripheral tolerance: Regulation of T-cell response in body (e.g. Tregs, anergy, apoptosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does the immune system prevent attacking its own cells?

A

Through immune tolerance, which prevents self-reactive immune responses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the key mechanisms of peripheral tolerance?

A

Anergy – T-cells recognise self-antigens but fail to activate due to lack of secondary signals (CD80/CD28)

Activation-induced cell death – Auto-reactive T-cells are destroyed (FAS-ligand mediated)

Regulatory T-cells – Suppress immune responses to prevent self-damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are cryptic antigens, and how can they cause immune-mediated disease?

A

Cryptic antigens aren’t expressed in thymus during development

If tissue damage exposes these antigens, immune system may mistakenly attack them

E.g.: Post-traumatic uveitis (immune response triggered by eye trauma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are common cytotoxic immune-mediated diseases in dogs?

A

IMHA (Immune-Mediated Hemolytic Anemia) – destruction of red blood cells

IMT (Immune-Mediated Thrombocytopenia) – destruction of platelets

IMPA (Immune-Mediated Polyarthritis) – inflammation of joint capsule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are common immune-mediated endocrine diseases in dogs?

A

Addison’s Disease (Hypoadrenocorticism) – destruction of adrenal glands, leading to no production of mineralocorticoids or glucocorticoids

Type 1 Diabetes – destruction of pancreatic islet cells, causing no insulin production

Hypothyroidism – destruction of thyroid follicular epithelium, leading to no thyroid hormone production

Exocrine Pancreatic Insufficiency (EPI) – destruction of pancreatic exocrine glands, resulting in no pancreatic digestive enzymes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the two broad categories of immune-mediated disease (IMD) management?

A

Reversible IMD – Use drugs to control immune response (e.g. IMHA)

Irreversible IMD – Replace missing hormone or function (e.g. Type 1 Diabetes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is Type II hypersensitivity, and how does it cause immune-mediated disease?

A

Antibody-mediated cytotoxicity (IgG or IgM bind to cell surface antigens)

Can lead to complement activation or macrophage destruction of targeted cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does Type II hypersensitivity cause IMHA (Immune-Mediated Haemolytic Anaemia)?

A

Autoantibodies (IgG or IgM) bind to red blood cell antigens

Cells are then:
- Opsonised for removal by macrophages in liver/spleen
- Destroyed by complement lysis

(More common in dogs than cats)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does Type II hypersensitivity cause Myasthenia Gravis?

A

Autoantibodies target acetylcholine receptors at neuromuscular junction

This blocks or destroys receptors, preventing nerve signal transmission

Leads to muscle weakness & fatigue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are two possible outcomes of autoantibody binding in Type II hypersensitivity?

A

Destruction of target cells (IMHA – red blood cells destroyed)

Blocking of receptor function (Myasthenia Gravis – acetylcholine receptor blocked)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is Type III hypersensitivity, and how does it cause immune-mediated disease?

A

Immune complex hypersensitivity – circulating antigen-antibody complexes deposit in small capillaries

Activates complement –> inflammation & tissue damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are common sites where immune complexes deposit, and what diseases do they cause? (Type III hypersensitivity)

A

Renal glomerulus → Glomerulonephritis

Synovium (joints) → Polyarthritis (IMPA)

Uveal tract (eye) → Uveitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How does immune complex deposition cause tissue damage? (Type III hypersensitivity)

A

Triggers inflammatory response –> tissue destruction

Can cause local ischaemia due to vessel inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is Type IV hypersensitivity, and how does it cause immune-mediated disease?

A

Cell-mediated hypersensitivity – CD8+ cytotoxic T cells attack cells displaying self-antigens

Leads to direct tissue destruction without antibody involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How does Type IV hypersensitivity cause hypothyroidism?

A

Cytotoxic T-cells destroy thyroid follicular cells

Results in thyroid hormone deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How do Th2 lymphocytes contribute to immune-mediated disease?

A

IL-4 & IL-5 drive B-cell activation, leading to autoantibody production

Autoantibodies cause Type II (cytotoxic) & Type III (immune complex) hypersensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How do Th1 lymphocytes contribute to immune-mediated disease?

A

IL-12 & IFN-γ drive cytotoxic T-cell activation

Causes Type IV hypersensitivity (T-cell-mediated destruction of self-tissues)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is a multisystemic immune-mediated disease (IMD)?

A

Most IMDs target specific organ or cell type due to single autoantigen

Multisystemic IMD occurs when immune system attacks multiple organs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the two mechanisms leading to multisystemic IMD?

A

Common Target – Autoantibodies target widely distributed antigens (e.g. SLE-like syndrome in dogs, where nucleic acids are attacked in multiple tissues)

Different Targets – Concurrent unrelated autoimmune diseases due to genetic predisposition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How do genetics influence immune-mediated diseases (IMD)?

A

Certain breeds (e.g. Cocker Spaniel) have genetic predisposition to IMD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What immune-mediated diseases are Cocker Spaniels at increased risk for?

A

Immune-Mediated Hemolytic Anemia (IMHA)

Immune-Mediated Thrombocytopenia (IMT)

Hypothyroidism

Keratoconjunctivitis Sicca (Dry Eye Syndrome)

Immune-Mediated Pancreatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Why are mid-to-older age dogs more likely to develop immune-mediated diseases (IMD)?

A

Age-related immune changes reduce immune regulation

Immunosenescence leads to reduced T-cell mediated immunity

Increased CD8+ cells & reduced CD4+ cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How does aging affect different parts of the immune system?

A

Cell-mediated immunity is most affected

Humoral immunity (antibody response) is less affected

Innate immunity remains largely preserved with minor defects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is primary (idiopathic) immune-mediated disease?

A

Occurs in genetically susceptible individuals without identifiable trigger

Likely involves multiple unknown factors

E.g. Immune-mediated haemolytic anaemia with no known cause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is secondary immune-mediated disease?

A

Triggered by distinct factor

E.g. drugs, infections, topical flea treatments causing hypersensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Why is identifying a trigger important in immune-mediated disease?

A

Primary IMD often requires long-term immune suppression

Secondary IMD (ie identifying trigger) may be treatable by removing trigger (e.g. stopping drug, treating infection)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

How can drugs trigger secondary immune-mediated disease (IMD)?

A

Some drugs act as haptens, bind to cells (RBC, platelets, WBC) & trigger immune response

Examples:
- Trimethoprim-sulphonamides (antibiotics) → Can cause IMHA or IMT
- Carbimazole & Methimazole (for hyperthyroid cats) → Can induce IMHA or IMT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

How can neoplastic diseases trigger secondary immune-mediated disease?

A

Tumours may express cryptic antigens or expose new antigens, triggering immune attack

Key associations:
Lymphoma & Splenic Hemangiosarcoma → Known triggers for IMHA & IMT

If IMHA or IMT is diagnosed, consider screening for underlying neoplasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

How can inflammation contribute to secondary immune-mediated disease (IMD)?

A

Chronic pancreatitis/enteropathy is associated with immune-mediated cytopenias

Acute enteritis is linked to Type III immune-mediated polyarthritis (IMPA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Why is it difficult to link infections to secondary immune-mediated disease (IMD)?

A

Infectious agents are hard to identify & difficult to culture

Some pathogens (e.g. Babesia, Leishmania, Ehrlichia) are sequestered in tissues

Triggering infection may have occurred weeks before IMD symptoms appear
- Time lag makes it harder to establish cause-&-effect relationship

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Why is identifying an infection (if possible) in IMD cases important?

A

Prevents misdiagnosis (e.g. distinguishing haemolytic parasites from IMHA)

Allows targeted treatment of infection, rather than just suppressing immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What are the key clinical signs of immune-mediated polyarthritis (IMPA)?

A

Pyrexia
Palpable joint effusions
Pain on joint manipulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What laboratory and radiographic findings are associated with immune-mediated polyarthritis (IMPA)?

A

C-reactive protein (CRP) elevated

Joint effusion analysis: Neutrophilic inflammation, but no infectious agents detected

Radiography: Joint effusions present, but no erosive changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is the pathophysiology of immune-mediated polyarthritis (IMPA)?

A

Type III hypersensitivity reaction
- Immune complex deposition in synovial basement membrane
- Complement cascade activation
- Recruitment of inflammatory cells (neutrophils & macrophages) → Release of nitric oxide, free radicals & proteases → tissue damage

Prompt treatment is crucial to prevent further damage

If trigger antigen is found, treating underlying cause may avoid need for immunosuppressive drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

How is immune-mediated polyarthritis (IMPA) categorized based on trigger factors?

A

Classified based on trigger factor:
- Type I (Idiopathic IMPA) – Most common, no trigger identified
- Type II – Associated with infection remote from joints (e.g. Lyme disease, Leishmaniasis, focal infections)
- Type III – Associated with inflammatory GI disease
- Type IV – Associated with neoplastic disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What clinical findings may indicate IMPA as part of a broader immune-mediated disease?

A

Joint disease along with:
- Glomerular disease
- Skin lesions (mucocutaneous junction erosions & ulcers)
- IMHA +/- thrombocytopenia (Evan’s Syndrome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Why is it necessary to reduce/stop overactive immune response?

A

To prevent further damage & manage symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

How does the severity of immune-mediated disease influence treatment goals?

A

Some diseases allow for partial control, while others require complete suppression to prevent life-threatening complications (e.g. Immune-mediated thrombocytopenia (risk of fatal bleeding))

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What is a major challenge when using immunosuppressive drugs?

A

Balancing disease control with significant adverse effects of drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What are the main functions of immunomodulatory drugs?

A

Stimulate, suppress, or modify immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Why is immune stimulation difficult, and what drug is commonly used for this purpose?

A

Achieving immune stimulation is challenging with limited options

Interferon omega is commercially available & used in severe viral infections (e.g. poxvirus & parvovirus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

How does immune modification work in allergy (and cancer therapy)?

A

Allergy immunotherapy increases T-regulatory cells, reducing IgE & T-helper cells

Some cancer treatments enhance immune responses to tumours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Why is immune suppression the most common immunomodulatory strategy?

A

Many immune-mediated diseases require suppression to prevent severe damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

What is an example of a broad vs. targeted immunosuppressive drug?

A

Broad drugs like steroids affect many immune pathways, while targeted drugs like Lokivetmab specifically block IL-31, reducing side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What are the challenges of using broad immunosuppressive drugs?

A

They can cause systemic immunosuppression, leading to adverse effects beyond intended target, increasing infection risk & other complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Why are steroids widely used as immunosuppressive agents?

A

They have broad immunosuppressive effects & can be used alone or in combination with other drugs

They are well-tolerated in cats, less so in dogs & can be problematic in horses

50
Q

How do steroids work at the cellular level?

A
  1. They bind to glucocorticoid receptors in cytoplasm of most nucleated cells
  2. Steroid-receptor complex translocates to nucleus, altering gene transcription in cell-specific manner (activate or inhibit genes –> varied effects)
51
Q

What additional effects do steroids have beyond gene transcription?

A

They exert non-genomic effects by stabilising immune cell membranes, reducing release of granules from mast cells, eosinophils & neutrophils, thereby limiting inflammation

52
Q

How do steroids reduce immune and inflammatory responses?

A

They reduce protein synthesis, leading to lower antibody production & inhibition of immune cell function

53
Q

What are the key effects of steroids on the immune system?

A

Suppress Immune Cell Function: - Reduce granulocyte, mast cell & monocyte-macrophage activity by stabilising membranes, preventing mediator release & reducing phagocytosis

Inhibit Cytokine Production:
- Downregulate inflammatory mediators like IL-1, IL-6 & TNF-alpha, reducing immune activation

Suppress T-cell Activity:
- Decrease T-cell function & can induce apoptosis, contributing to their use in cancer therapy

Reduce Antibody Production:
- Gradual suppression of B-cell function leads to lower antibody levels over time

Downregulate Fc Receptors:
- Reduces antibody binding, further dampening immune responses

54
Q

Why do steroids cause widespread metabolic effects?

A

They are hormonal drugs that act systemically, leading to inevitable side effects

55
Q

What are the key metabolic effects of steroids?

A

Increased gluconeogenesis → Higher blood glucose & insulin resistance

Protein catabolism → Muscle wasting & increased blood proteins

Lipolysis & fat redistribution → Altered body fat distribution

56
Q

How do steroids affect the skin and connective tissue?

A

Cause cutaneous atrophy –> thin, fragile skin & hair loss

57
Q

What is the effect of steroids on calcium metabolism?

A

Mobilise calcium –> calcinosis cutis (calcium deposition in skin)

58
Q

How do steroids impact the gastrointestinal system?

A

They increase gastric acid secretion, raising risk of ulcers

59
Q

What additional effects do some steroids have due to mineralocorticoid activity?

A

Can cause salt & water retention, affecting blood pressure, heart & kidney function

60
Q

Why can high-dose steroid use lead to euthanasia in some cases?

A

Severe side effects (esp. metabolic & tissue damage) can outweigh benefits of treatment

61
Q

How does Azathioprine cause immunosuppression, and why does it mainly affect immune cells?

A

Azathioprine is metabolised in liver to 6-mercaptopurine, which incorporates into DNA, disrupting rapidly dividing cells like bone marrow & immune cells

Since these cells undergo frequent mitosis, they are more affected, while slower-dividing cells (e.g. hepatocytes) experience less impact

62
Q

How is Azathioprine metabolised, and why do some individuals experience severe side effects?

A

Azathioprine is broken down by xanthine oxidase & thiopurine methyltransferase (TPMT) into inactive metabolites for excretion

Some dogs lack TPMT enzyme, leading to toxic accumulation of active metabolites & increased side effects

63
Q

What are the major risks associated with Azathioprine?

A

Pancreatitis → Often linked to concurrent steroid use; usually resolves when steroids are withdrawn

Hepatotoxicity → Can be severe & may not resolve with drug withdrawal

64
Q

Why should Azathioprine never be used in cats?

A

Can’t tolerate drug well due to severe toxicity risks & difficulty in dosing

65
Q

Why does Azathioprine require haematology and biochemistry monitoring, and what are the expected haematologic side effects?

A

Mild anaemia & lymphopenia are common & can indicate appropriate therapeutic dose

However, drug’s effects are variable, so monitoring every 2-4 weeks is essential to ensure safe dosing & detect severe side effects early

66
Q

What is Chlorambucil, and why is it commonly used in cats?

A

Alkylating agent derived from nitrogen mustard with cytotoxic effects on DNA.

Commonly used in cats as alternative to Azathioprine

67
Q

How does Chlorambucil work, and how does its action compare to Azathioprine?

A

It cross-links DNA, causing cytotoxic effects

Has slower onset (6 weeks) than Azathioprine (2-3 weeks)

Haematology & biochemistry monitoring every 2 weeks initially, then extending to every 4 weeks once stable

68
Q

What are the common side effects of Chlorambucil, and how can they be managed?

A

Myelosuppression (less common than Azathioprine) → requires monitoring

GI signs (more with daily dosing): anorexia, vomiting, diarrhea

Reducing dose frequency (e.g. every other day or extended intervals in small cats) can help minimise GI side effects

69
Q

How does Mycophenolate Mofetil work?

A

Inhibits de novo purine synthesis, disrupting DNA synthesis & suppressing both T & B cells more than other immune cells

Faster acting than drugs like azathioprine or chlorambucil, taking only a few days to take effect instead of weeks

70
Q

In which conditions is Mycophenolate Mofetil particularly useful?

A

Often used as adjuvant drug, esp. in canine pemphigus foliaceus (pF) & sporadically in other immune-mediated diseases

71
Q

What are the most significant side effects of Mycophenolate Mofetil?

A

Acute severe GI toxicity—some dogs develop vomiting, diarrhea, or become systemically unwell, making drug unsuitable for them

Hepatitis may develop (less common)

72
Q

How does Ciclosporin work as an immunosuppressant?

A
  1. It binds to cytoplasmic cyclophilin
  2. Forms complex that inhibits calcineurin (preventing dephosphorylation of NF-AT)
  3. Leads to reduced IL-2 & cytokine activation
  4. Results in suppressed T-cell function

Unlike steroids, Ciclosporin doesn’t cause significant metabolic effects, making it a more targeted immunosuppressant

73
Q

In which conditions is Ciclosporin licensed for use?

A

Licensed for atopic dermatitis in dogs & non-flea hypersensitivity disease in cats

74
Q

How is Ciclosporin dosed in immune-mediated diseases?

A

Used at higher doses for immune suppression & at lower doses for immunomodulation in conditions like allergic skin disease

75
Q

Why is Ciclosporin a poor choice for rapidly progressive immune-mediated diseases?

A

Has very slow onset of action, making it unsuitable for life-threatening diseases like IMHA or immune-mediated thrombocytopenia that require immediate control

76
Q

When is Ciclosporin most useful?

A

Best suited for T-cell mediated diseases or as secondary drug in antibody-mediated diseases

Effective in chronic conditions like pemphigus foliaceus, cutaneous lupus & severe symmetric lupoid onychodystrophy (SLO)

77
Q

What are the common side effects of Ciclosporin?

A

Gastrointestinal issues: Vomiting and diarrhea

Metabolic effects: Hirsutism (abnormal hair growth), gum hyperplasia

Immunosuppression: Increased risk of infections

78
Q

Why should Ciclosporin use be monitored with other medications?

A

Its metabolised by cytochrome P450 enzyme system, which interacts with other drugs

79
Q

How does Leflunomide work as an immunosuppressant?

A

Inhibits mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), preventing expansion of activated & autoimmune lymphocytes, effectively slowing down immune response

80
Q

In which immune-mediated diseases is Leflunomide used?

A

Immune-mediated polyarthritis (IMPA)

Immune-mediated hemolytic anemia (IMHA)

Immune-mediated thrombocytopenia (IMT)

81
Q

What are the potential side effects of Leflunomide?

A

Diarrhoea
Lethargy
Unexplained haemorrhage
Thrombocytopenia
Increased liver enzymes

82
Q

How does Oclacitinib work as an immunosuppressant?

A

It inhibits JAK-1, blocking cytokine receptor signaling for cytokines in IL-2 & IL-6 family, which includes IL-2, IL-10, IL-4, IL-13, and IL-31

83
Q

What is Oclacitinib licensed for, and how is it being used beyond that?

A

Licensed for canine atopic dermatitis & allergic skin disease

Higher doses used for immune-mediated diseases, particularly as steroid-sparing agent

84
Q

Why is Oclacitinib not preferred for critical immune-mediated diseases?

A

Not as potent as other immunosuppressants & may be less effective for severe conditions like IMHA or IMT

Better suited for maintenance therapy or non-critical diseases

85
Q

What are the main side effects of Oclacitinib?

A

Neutropenia
Haematological abnormalities
Diarrhoea (uncommon)

86
Q

How do Omega-3 fatty acids help in inflammatory and immune-mediated diseases?

A

They reduce production of inflammatory mediators by interfering with arachidonic acid pathway & promoting synthesis of anti-inflammatory factors, helping to modulate both innate & adaptive immune responses

87
Q

What is Vitamin E used for in immune-mediated diseases?

A

Acts as adjunct antioxidative treatment, particularly in sterile pyogranulomatous panniculitis

88
Q

How does Vitamin D influence the immune system?

A

Enhances innate immunity by boosting immune response against pathogens & modulates adaptive immunity by influencing T-cell activation & antigen-presenting cells

89
Q

What is main risk of excessive Vitamin D supplementation?

A

Hypercalcemia, which can lead to renal failure if prolonged

90
Q

How does glutamine support the immune system and gut health?

A

Normally non-essential amino acid, but in diseased states, it becomes essential

Preferred energy source for enterocytes, supporting gut barrier integrity

Plays role in nitrogen metabolism, immune modulation & antioxidant function

91
Q

What is potential role of arginine in immune-mediated disease?

A

May have immune-enhancing properties, esp. in critical illness

92
Q

What is the typical strategy for using immunosuppressive drugs in immune-mediated diseases (IMD)?

A

Most cases start with high-dose steroids, & additional drugs are added later to reduce steroid side effects or enhance immunosuppression

93
Q

Which drugs are commonly added to reduce steroid adverse effects?

A
  1. Azathioprine or Chlorambucil – used early as second-line agents
  2. Ciclosporin – slower-acting but more targeted, esp. in T-cell mediated diseases like erythema multiforme or discoid lupus erythematosus
  3. Mycophenolate, Oclacitinib, Leflunomide – typically used when other options have failed, with variable success
94
Q

What is the main risk of using multiple immunosuppressive drugs together?

A

Increased risk of profound immunosuppression, leading to higher susceptibility to infections

While none of these drugs have strong contraindications when combined, unexpected adverse effects can still occur

95
Q

What factors should be considered when choosing immunosuppressive therapy?

A

Phase of treatment: Induction vs. Maintenance

Severity: Is disease life-threatening?

Mechanism of immunological damage:
- Humoral (antibody-mediated) → often requires steroids
- Cellular (T-cell/NK cell damage) → may respond better to calcineurin inhibitors (e.g. Ciclosporin)

96
Q

How do direct vs. indirect immunosuppressive drugs differ in their use?

A

Direct-acting drugs work immediately on immune cells & are often used for acute, severe cases

Indirect-acting drugs have more delayed onset but are better for maintenance therapy

97
Q

What are the key stages in managing immunosuppressive therapy?

98
Q

What is the underlying cause of IMHA?

A

IMHA occurs when immune system mistakenly targets & destroys red blood cells

99
Q

What are the two main types of IMHA?

A

Primary (idiopathic - likely genetic or environmental predisposition) & Secondary (caused by underlying disease, infection, neoplasia, or drugs)

100
Q

How does IMHA lead to pyrexia?

A

Pro-inflammatory cytokines act on hypothalamus, altering body’s temperature regulation

Pyrexia could also indicate underlying infectious disease as trigger factor for IMHA

101
Q

Why does IMHA cause jaundice?

A

Haemolysis releases bilirubin, which accumulates when liver can’t process it fast enough

102
Q

What causes splenomegaly in IMHA?

A

Spleen is site of phagocytosis of opsonised RBCs (RBCs bound to circulating antibody &/or complement) by macrophages

Could also occur because spleen is site of secondary haematopoiesis activated in response to anaemia

103
Q

What are common clinical signs of IMHA?

A

Lethargy, pale/jaundiced mucous membranes, tachycardia, tachypnea, pyrexia, lymphadenopathy, splenomegaly

104
Q

Why does IMHA lead to tachycardia and tachypnea?

A

Decreased oxygen-carrying capacity triggers compensatory increases in heart & resp rates

105
Q

What are common quick tests to assess anaemia severity in suspected IMHA?

A

Packed Cell Volume (PCV) & Total Solids (TS)

106
Q

Why is normal total solids (TS) important in IMHA?

A

It helps differentiate IMHA from blood loss anaemia, where both PCV & TS would decrease

107
Q

How can you tell if anaemia is regenerative on blood smear and haematology?

A

Blood smear - look for markers of regeneration:
- Polychromasia – immature RBC
- Anisocytosis – variable RBC sizes (immature tend to be larger than mature)
- Increased nucleated RBC

Haematology:
- High MCV
- High reticulocyte count
- Low MCHC

108
Q

Label S, P & NE

A

P= large polychromatic RBCs likely reticulocytes (immature RBC)

ME= nucleated RBC (erythrocyte)

S= spherocytes

109
Q

Why might anaemia appear non-regenerative early in IMHA?

A

Bone marrow takes 3-5 days to mount a regenerative response

110
Q

What additional tests help diagnose IMHA?

A

Blood smear
- Look for spherocytes & neutrophilia

Look for evidence of extreme type II hypersensitivity response:
- Evidence of autoagglutination (speckles on surface of blood tube (EDTA best anticoagulant) seen when tipped gently)
- Saline agglutination test
- Coombs test (if saline agglutination test is negative)

PCR for infectious causes

Radiographs & ultrasound for underlying disease

111
Q

What are spherocytes?

A

Smaller & rounder/denser than normal RBCs (no central pallor seen)

They are fragments of RBCs that result from damage by partial phagocytosis by macrophages in spleen &/or liver

112
Q

What is autoagglutination?

A

IgM/IgG auto antibodies attach to antigens on surface of RBCs & draw together RBC –> clumping: autoagglutination

113
Q

How is the saline agglutination test done?

A

Mix 1 drop of EDTA blood with 4 drops of saline on slide

Examine under microscope to assess for autoagglutination

Helps differentiate true agglutination (grape-like clusters due to antibody binding) from rouleaux formation (stacks of coins due to increased plasma proteins)

True agglutination supports diagnosis of immune-mediated hemolytic anemia (IMHA)

114
Q

What is the purpose of the Coombs test in diagnosing IMHA?

A

Direct antiglobulin test used if saline agglutination test is -ve

Detects immunoglobulins (auto antibody) &/or complement bound to RBCs in dogs with IMHA

115
Q

Why is it important to rule out secondary causes before treating IMHA?

A

Treating underlying cause (e.g. infection, neoplasia) may resolve IMHA without need for strong immunosuppressants

116
Q

What are the possible mechanisms causing red blood cell (RBC) damage in IMHA?

A

Primary IMHA (1ry IMHA)
- Idiopathic: No underlying cause identified
- Autoantibody to RBC membrane antigen: Immune system attacks its own RBCs

Secondary IMHA (2ry IMHA)
- Cross-reacting antibodies against infectious agents
- Antibody against drug-adherent RBCs
- Drug, infection, or neoplasia modifies RBC antigen or exposes hidden antigens

Alloantibody-Mediated IMHA
- Blood transfusion reaction (incompatible donor-recipient)
- Neonatal isoerythrolysis (maternal antibodies attack neonatal RBCs)

117
Q

What are the main treatment goals for IMHA?

A

Suppress abnormal immune response

Provide supportive care

Manage complications (e.g. thrombosis & transfusion reactions)

118
Q

How do you monitor response to IMHA treatment?

A

PCV trends, reticulocyte count, resolution of autoagglutination, improved clinical signs

119
Q

What are the first-line immunosuppressive drugs for IMHA?

A

Prednisolone or dexamethasone

120
Q

When is a blood transfusion indicated in IMHA, and why is packed RBC preferred?

A

Indicated when PCV is critically low & patient is unstable

Packed RBCs preferred over whole blood as they provide oxygen-carrying capacity without volume overload